AR032763A1 - Compuestos pirazol-tiazol, composicion farmaceutica que lo contiene, y el uso de dicho compuesto en la fabricacion de medicamentos para inhibir quinasas ciclino-dependientes - Google Patents

Compuestos pirazol-tiazol, composicion farmaceutica que lo contiene, y el uso de dicho compuesto en la fabricacion de medicamentos para inhibir quinasas ciclino-dependientes

Info

Publication number
AR032763A1
AR032763A1 ARP010103827A ARP010103827A AR032763A1 AR 032763 A1 AR032763 A1 AR 032763A1 AR P010103827 A ARP010103827 A AR P010103827A AR P010103827 A ARP010103827 A AR P010103827A AR 032763 A1 AR032763 A1 AR 032763A1
Authority
AR
Argentina
Prior art keywords
compounds
inhibit
manufacture
dependent kinases
tiazol
Prior art date
Application number
ARP010103827A
Other languages
English (en)
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of AR032763A1 publication Critical patent/AR032763A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos de pirozol-tiazol de formula (1); donde R1 es un grupo seleccionado de grupos alquilo, arilo, heteroarilo, cicloalquilo, y heterocicloalquilo sustituidos y no sustituidos: y R2 es un grupo seleccionado de grupos alquilo, aril, heteroaril, cicloalquilo, heterocicloalquilo sustituidos y no sustituidos, con condicion de que R1 y R2 no sean ambos un fenilo no sustituido: o una sal farmacéuticamente aceptable, una forma multimérica, una prodroga, o su metabolito farmacologicamente activo o una sal farmacéuticamente aceptable de dicho metabolito. Estos compuestos modulan o inhiben la actividad de las quinasas ciclina-dependientes y las composiciones farmacéuticas que los contienen son capaces de mediar en enfermedades ciclina-dependientes para modular o inhibir la proliferacion indeseada de células. El uso de dichos compuestos en la fabricacion de medicamentos para tratar el cáncer así como otros estados de enfermedad asociados con angiogénesis indeseada o proliferacion celular, tales como retinopatía diabética, glaucoma neovascular, artritis reumatoide, y psoriasis, por medio de la administracion de cantidades eficaces de dichos compuestos.
ARP010103827A 2000-08-09 2001-08-09 Compuestos pirazol-tiazol, composicion farmaceutica que lo contiene, y el uso de dicho compuesto en la fabricacion de medicamentos para inhibir quinasas ciclino-dependientes AR032763A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22398900P 2000-08-09 2000-08-09

Publications (1)

Publication Number Publication Date
AR032763A1 true AR032763A1 (es) 2003-11-26

Family

ID=22838822

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103827A AR032763A1 (es) 2000-08-09 2001-08-09 Compuestos pirazol-tiazol, composicion farmaceutica que lo contiene, y el uso de dicho compuesto en la fabricacion de medicamentos para inhibir quinasas ciclino-dependientes

Country Status (15)

Country Link
US (1) US6566363B2 (es)
EP (1) EP1307462A2 (es)
JP (1) JP2004505983A (es)
AR (1) AR032763A1 (es)
AU (1) AU2001277285A1 (es)
BR (1) BR0113139A (es)
CA (1) CA2411928A1 (es)
GT (1) GT200100162A (es)
HK (1) HK1052354A1 (es)
MX (1) MXPA03001189A (es)
MY (1) MY117667A (es)
PA (1) PA8524801A1 (es)
PE (1) PE20020304A1 (es)
UY (1) UY26877A1 (es)
WO (1) WO2002012250A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
EP1925306A3 (en) * 2002-04-30 2008-09-17 Alcon, Inc. Agents which Regulate, Inhibit, or Modulate the Activity and/or Expression of Connective Tissue Growth Factor (CTGF) to Lower Intraocular Pressure
AU2003221762B2 (en) * 2002-04-30 2008-09-25 Alcon, Inc. Agents which regulate, inhibit or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
US6818663B2 (en) * 2002-05-17 2004-11-16 Hoffmann-La Roches Diaminothiazoles
CA2516234A1 (en) * 2003-02-21 2004-09-02 Pfizer Inc. N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
EP1713814A1 (en) * 2003-12-17 2006-10-25 SGX Pharmaceuticals, Inc. Bicyclic pyrazolo-fused compounds as protein kinase modulators
TW200526224A (en) * 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
EP1732934A1 (en) 2004-03-31 2006-12-20 Lexicon Genetics Incorporated Novel thiazolopyrazoles and methods of their use
US7211576B2 (en) 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
FR2878442B1 (fr) * 2004-11-29 2008-10-24 Aventis Pharma Sa THIENO(2,3-c)PYRAZOLES SUBSTITUES, PROCEDE DE PREPARATION, COMPOSITIONS LES CONTENANT ET UTILISATION
CA2630079A1 (en) * 2005-11-16 2007-05-24 Sgx Pharmaceuticals, Inc. Pyrazolothiazole protein kinase modulators
WO2009040552A2 (en) 2007-09-27 2009-04-02 Centro Nacional De Investigaciones Oncológicas (Cnio) Substituted imidazo (2, 1-b) -1, 3, 4-thiazole compounds, their pharmaceutical compositions and uses thereof
JP5490137B2 (ja) * 2008-12-19 2014-05-14 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ プロテインキナーゼ阻害薬としての二環式ピラゾール
EP2414369B1 (en) 2009-04-02 2015-08-12 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Imidazo[2,1-b][1,3,4]thiadiazole derivatives
DE102009058280A1 (de) * 2009-12-14 2011-06-16 Merck Patent Gmbh Thiazolderivate

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2429195A1 (de) * 1974-06-18 1976-02-05 Basf Ag 2-amino-pyrazolo eckige klammer auf 3,4-d eckige klammer zu thiazole
US5625031A (en) 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
EP0788358B1 (en) * 1994-11-10 2004-03-31 Millennium Pharmaceuticals, Inc. Use of pyrazole compounds for the treatment of glomerulonephritis, cancer, atherosclerosis or restenosis
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US6495526B2 (en) 1996-01-23 2002-12-17 Gpc Biotech, Inc. Inhibitors of cell-cycle progression and uses related thereto
GB9608435D0 (en) 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
FR2752523B1 (fr) * 1996-08-26 1998-10-02 Oreal Compositions de teinture des fibres keratiniques contenant des pyrazolo-(3,4-d)-thiazoles leur utilisation pour la teinture comme coupleurs, procede de teinture
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
ATE391719T1 (de) 1997-02-05 2008-04-15 Warner Lambert Co Pyrido (2,3-d) pyrimidine und 4-amino-primidine als inhibitoren der zellulären proliferation
CA2294244A1 (en) 1997-07-12 1999-01-21 Cancer Research Campaign Technology Limited Cyclin dependent kinase inhibiting purine derivatives
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
ATE249217T1 (de) * 1997-10-06 2003-09-15 Abbott Gmbh & Co Kg Indeno(1,2-c)-,naphtho(1,2-c)-und benzo(6, 7)cyclohepta(1,2-c)pyrazolderivate
EP1056732B1 (en) * 1997-10-27 2006-01-11 Agouron Pharmaceuticals, Inc. 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
SK12912000A3 (sk) 1998-02-26 2001-08-06 Aventis Pharmaceuticals Inc. 6,9-disubstituované 2-[trans-(4-aminocyklohexyl)amino]puríny, farmaceutické prostriedky obsahujúce tieto zlúčeniny a použitie
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
AU767409B2 (en) * 1998-04-21 2003-11-06 Du Pont Pharmaceuticals Company 5-aminoindeno(1,2-C)pyrazol-4-ones as anti-cancer and anti-proliferative agents
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця

Also Published As

Publication number Publication date
JP2004505983A (ja) 2004-02-26
MXPA03001189A (es) 2004-05-14
HK1052354A1 (zh) 2003-09-11
MY117667A (en) 2004-07-31
PA8524801A1 (es) 2002-04-25
PE20020304A1 (es) 2002-05-29
WO2002012250A3 (en) 2002-09-06
UY26877A1 (es) 2002-03-22
WO2002012250A2 (en) 2002-02-14
AU2001277285A1 (en) 2002-02-18
EP1307462A2 (en) 2003-05-07
WO2002012250B1 (en) 2002-11-21
US6566363B2 (en) 2003-05-20
BR0113139A (pt) 2003-06-24
CA2411928A1 (en) 2002-02-14
US20020049215A1 (en) 2002-04-25
GT200100162A (es) 2002-05-16

Similar Documents

Publication Publication Date Title
AR032438A1 (es) Compuesto derivado de indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento para tratar enfermedades proteinquinasa dependientes
AR032763A1 (es) Compuestos pirazol-tiazol, composicion farmaceutica que lo contiene, y el uso de dicho compuesto en la fabricacion de medicamentos para inhibir quinasas ciclino-dependientes
AR035554A1 (es) Compuesto derivado de indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de quinasa proteina.
AR030211A1 (es) Compuestos derivados de amino-pirazol, composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por la actividad de la quinasa proteinica
AR029222A1 (es) Compuesto derivado de amida, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para tratar enfermedades mediadas por la proteinquinasa
RU2403258C2 (ru) Тиазолилдигидроиндазолы
WO2022228387A1 (en) Compounds as parp inhibitors
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR048340A1 (es) Compuestos de acido alfa aril o heteroaril metil beta piperidino propanoico como antagonistas del receptor orl1, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para tratar enfermedades mediadas por orl1.
UY26143A1 (es) Derivados heterocíclicos útiles como agentes anticancerosos
AR042510A1 (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
GT200400136A (es) Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibirlaproliferacion celular.
JP2015501833A5 (es)
AR050952A1 (es) Derivados de indazolona; procesos para su obtencion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta - hsd1.
CA2382129A1 (en) Novel derivatives of flavones, xanthones and coumarins
AR057869A1 (es) Compuesto cuaternario de (alfa)-aminocarboxiamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para preparar dicho compuesto
RU2002108565A (ru) Новые производные флавонов, ксантонов и кумаринов
EA200201201A1 (ru) Соединения с сульфамидной группой и содержащие эти соединения фармацевтические композиции
WO2021022076A1 (en) Molecules and methods related to treatment of uncontrolled cellular proliferation
KR20220034829A (ko) Pd-l1 억제제로서의 인단
AR030007A1 (es) Compuesto de ciclohexilo, su uso para la manufactura de un medicamento, agente de diagnostico, composicion farmaceutica que lo contiene, proceso para su preparacion, compuestos para su exclusivo uso en la preparacion de dichos compuestos de ciclohexilo, y metodo de tratamiento
AR032607A1 (es) Composiciones farmaceuticas que contienen sales de hidroxieicosatetraenoato, y el uso de las mismas para la manufactura de un medicamento para el tratamiento de desordenes del ojo seco
MXPA05012377A (es) Derivados de imidazotiazoles e imidazoxazol como inhibidores de p38.
AR012436A1 (es) Compuestos de 4-aminopirido[2,3-d]pirimidina 5,7-disustituidos, composicion farmaceutica que los comprende, el uso de los mismos para lamanufactura de medicamentos, un procedimiento para su preparacion.

Legal Events

Date Code Title Description
FB Suspension of granting procedure